Tiotropium bromide
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2004
- First approval year
- 2004
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Tiotropium bromide
- Molecular weight
- 490.44
- Structure (SMILES)
- C[N+]1(C)[C@@H]2C[C@@H](OC(=O)C(O)(c3cccs3)c3cccs3)C[C@H]1[C@@H]1O[C@@H]12.O.[Br-]
- braltus
- Braltus
- spiriva
- Spiriva
- spiriva respimat
- Spiriva respimat
- 1 alpha 2 beta 4 beta 5 alpha 7 beta 7 hydroxydi 2 thienylacetyl oxy 9 9 dimethyl 3 oxa 9 azoniatricyclo 3 3 1 0 sup 2 4 nonane bromide monohydrate
- 1.ALPHA., 2.BETA., 4.BETA, 5.ALPHA, 7.BETA-7-((HYDROXYDI-2-THIENYLACETYL)OXY)-9,9-DIMETHYL-3-OXA-9-AZONIATRICYCLO(3.3.1.0 SUP(2,4))NONANE BROMIDE MONOHYDRATE
- 6 beta 7 beta epoxy 3 beta hydroxy 8 methyl 1 alpha h 5 alpha h tropanium bromide di 2 thienylglycolate monohydrate
- 6.BETA.,7.BETA.-EPOXY-3.BETA.-HYDROXY-8-METHYL-1.ALPHA.H,5.ALPHA.H-TROPANIUM BROMIDE, DI-2-THIENYLGLYCOLATE MONOHYDRATE
- ba 679 br
- BA 679 BR
- ba 679br
- BA-679 BR
- BA-679-BR
- BA-679BR
- braltus
- Braltus
- bromure de tiotropium
- Bromure de tiotropium
- bromuro de tiotropio
- Bromuro de tiotropio
- Reference Product (Spiriva®)
- Spiriva
- SPIRIVA
- Spiriva Respimat
- Spiriva Respimat 2.5 μg
- Spiriva®
- Spiriva® Respimat®
- Spiriva® Respimat® 2,5 μg
- Tiotropium (Spiriva) inhalation capsule 18 ug
And 22 more, listed on the interactive page.
- ChEMBL ID
- CHEMBL3545181
- InChIKey
- MQLXPRBEAHBZTK-SEINRUQRSA-M
- RxNorm IDs (RxCUI)
- 1298831
- FDA ingredient codes (UNII)
- L64SXO195N
- R03BB04
- R03BB54
Sources for recorded values
- 186691-13-4
- 411207-31-3
- Applicant
- BOEHRINGER INGELHEIM
- Approval date
- 30 Jan 2004
- Application number
- NDA021395
- Patents
- 10
- Designations
- 1
- Earliest recorded loss of exclusivity
- 16 Apr 2031
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- tiotropium
- Type
- Synthetic organic
- Drug name stem
- -ium; -trop-
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- topical
- Action type
- Antagonist
- Target
- M<sub>1</sub> receptor
- Gene symbol
- M<sub>1</sub> receptor
- Action type
- Antagonist
- Target
- M<sub>2</sub> receptor
- Gene symbol
- M<sub>2</sub> receptor
- Action type
- Antagonist
- Target
- M<sub>4</sub> receptor
- Gene symbol
- M<sub>4</sub> receptor
- Action type
- Antagonist
- Target
- M<sub>5</sub> receptor
- Gene symbol
- M<sub>5</sub> receptor
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M2 receptor
- Gene symbol
- CHRM2
- Protein identifier
- P08172
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M4 receptor
- Gene symbol
- CHRM4
- Protein identifier
- P08173
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M5 receptor
- Gene symbol
- CHRM5
- Protein identifier
- P08912
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M1 receptor
- Gene symbol
- CHRM1
- Protein identifier
- P11229
- Affinity units
- pKi
- Action
- Antagonist
- Action type
- Antagonist
- Target
- M3 receptor
- Gene symbol
- CHRM3
- Protein identifier
- P20309
- Affinity units
- pKi
- Primary target
- Yes
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
- Action type
- Antagonist
- Target
- Muscarinic acetylcholine receptor M3
- Protein identifier
- P20309
Open Targets mechanisms
- Mechanism
- Muscarinic acetylcholine receptor M3 antagonist
- Action type
- Antagonist
- Target
- Muscarinic acetylcholine receptor M3
DrugCentral mechanisms
- Action type
- Antagonist
- Gene symbol
- CHRM3
- Protein identifier
- P20309
- Organism
- Homo sapiens
- Target development level
- Clinical
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Emphysema
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000464
- Subject identifier
- D004646
- Condition
- Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000616
- Subject identifier
- D009369
- Condition
- Bronchitis, Chronic
- Highest recorded phase
- 4
- Condition identifier
- EFO:0006505
- Subject identifier
- D029481
- Condition
- Lung Diseases, Obstructive
- Highest recorded phase
- 4
- Condition identifier
- HP:0006536
- Subject identifier
- D008173
- Condition
- Bronchial Spasm
- Highest recorded phase
- 4
- Condition identifier
- HP:4000007
- Subject identifier
- D001986
- Condition
- Asthma
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001249
- Condition
- Bronchial Spasm
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0004979
- Subject identifier
- D001986
- Condition
- Cystic Fibrosis
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0009061
- Subject identifier
- D003550
- Condition
- Spinal Cord Injuries
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0043797
- Subject identifier
- D013119
- Condition identifier
- EFO_0000341
- Condition identifier
- EFO_0000464
- Condition identifier
- EFO_0000616
- Highest recorded phase
- 2
- Condition identifier
- EFO_0006505
- Condition identifier
- EFO_0009661
- Condition identifier
- HP_0006536
- Condition identifier
- HP_0006536
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0003781
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004849
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0004979
- Condition identifier
- MONDO_0004979
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005002
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005249
- Condition identifier
- MONDO_0005607
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0009061
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0043797
- Highest recorded phase
- 2
- Event
- asthma
- Reports
- 1,870
- Reporting signal score
- 5,033.83
- Event
- asthma-chronic obstructive pulmonary disease overlap syndrome
- Reports
- 73
- Reporting signal score
- 346.021
- Event
- balance disorder
- Reports
- 242
- Reporting signal score
- 219.456
- Event
- benign prostatic hyperplasia
- Reports
- 74
- Reporting signal score
- 159.053
- Event
- blood calcium decreased
- Reports
- 169
- Reporting signal score
- 335.893
- Event
- blood count abnormal
- Reports
- 550
- Reporting signal score
- 1,538.13
- Event
- blood test abnormal
- Reports
- 121
- Reporting signal score
- 221.948
- Event
- breath sounds abnormal
- Reports
- 95
- Reporting signal score
- 230.827
- Event
- bronchial obstruction
- Reports
- 50
- Reporting signal score
- 139.407
- Event
- bronchial secretion retention
- Reports
- 43
- Reporting signal score
- 141.262
- Event
- bronchial wall thickening
- Reports
- 57
- Reporting signal score
- 214.979
- Event
- bronchiectasis
- Reports
- 164
- Reporting signal score
- 421.953
- Event
- bronchopulmonary aspergillosis allergic
- Reports
- 47
- Reporting signal score
- 169.993
- Event
- chest discomfort
- Reports
- 471
- Reporting signal score
- 540.411
- Event
- chronic obstructive pulmonary disease
- Reports
- 868
- Reporting signal score
- 2,201.31
- Event
- cognitive disorder
- Reports
- 234
- Reporting signal score
- 284.649
- Event
- constipation
- Reports
- 353
- Reporting signal score
- 152.343
- Event
- cough
- Reports
- 1,152
- Reporting signal score
- 1,355.41
- Event
- creatinine renal clearance decreased
- Reports
- 169
- Reporting signal score
- 439.02
- Event
- depressed level of consciousness
- Reports
- 199
- Reporting signal score
- 180.792
- Event
- diarrhoea
- Reports
- 116
- Reporting signal score
- 139.127
- Event
- dry mouth
- Reports
- 295
- Reporting signal score
- 357.227
- Event
- dysphonia
- Reports
- 187
- Reporting signal score
- 180.543
- Event
- dyspnoea
- Reports
- 2,411
- Reporting signal score
- 2,828.57
- Event
- dyspnoea exacerbated
- Reports
- 48
- Reporting signal score
- 177.636
And 38 more, listed on the interactive page.
- NCT00106821
- NCT00144326
- NCT00157235
- NCT00239408
- NCT00274027
- NCT00274079
- NCT00274508
- NCT00274573
- NCT00292448
- NCT00308191
- NCT00361959
- NCT00412204
- NCT00496470
- NCT00528996
- NCT00555022
- NCT00563381
- NCT00568503
- NCT00696020
- NCT00720499
- NCT00784550
- NCT01040403
- NCT01124422
- NCT01316900
- NCT01316913
- NCT01437748
And 39 more, listed on the interactive page.
- Dose
- 2 inhalations of 2.5 mcg or 1.25 mcg per actuation
- Route
- Inhalation
- How often
- Once daily
- Administer as two inhalations
- Do not exceed 2 inhalations in 24 hours
- Hydrogen bond acceptors
- 6
- Hydrogen bond donors
- 1
- Polar surface area
- 59.06
- Calculated partition coefficient (ALogP)
- 2.35
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 4
- Heavy atoms
- 28
- Molecular formula
- C19H24BrNO5S2
- Natural product
- No
- 0597-0075
- 0597-0155
- 68180-964
- 50090-4248
- 50090-7645
Plasma protein binding
- Median
- 48
- Mean
- 48
- Minimum
- 48
- Maximum
- 48
- Unit
- %
- Assays
- 2
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- PPB
Related records
Trials (120)
- 12-week Treatment With Inhaled Tiotropium (18 mcg Once Daily) on Lung Function and Static Lung Volumes in Stable, Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Patients. Correlation to Dyspnoea Scales
- 24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003, Open-Label Spiriva® Respimat® as an Active Control, and Placebo
- 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease
- 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease
- 24hr Effects of Tiotropium Bromide in Tetraplegia
- A 24-Week Study to Evaluate the Safety and Efficacy of ADVAIR DISKUS® Inhaler 250/50mcg Plus SPIRIVA HANDIHALER® Inhaler Versus SPIRIVA HANDIHALER® Inhaler Plus Placebo DISKUS® Inhaler in Subjects With Chronic Obstructive Pulmonary Disease (COPD).
- A 3 Way Cross-over Study Evaluating the Effects of ADOAIR Twice Daily Plus Tiotropium Bromide Once Daily Compared With the Individual Treatments of Japanese Subjects
- A 6-week Dose Ranging Study of CHF 5259 pMDI in Subjects With Chronic Obstructive Pulmonary Disease
- A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of TQC3302 Inhalation Spray in Healthy Adult Subjects
- A Comparison of 18g of Tiotropium Inhalation Capsules Once Daily and Atrovent Metered Dose Inhaler (2 Puffs of 20g, 4 Times Daily) in a Double-Blind, Double-Dummy, Efficacy and Safety Study in Adults With Chronic Obstructive Pulmonary Disease (COPD)
- A Long-Term Safety Trial of Treatment With Nebulized SUN-101 in Patients With COPD
- A Phase IIIB Study to Compare the Efficacy and Safety of Concomitant Treatment in Patients With COPD
- A Randomised, Double-blind, Crossover Study of Ba679BR Respimat in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- A Randomised, Double-blind, Placebo-controlled, 12 Week Trial to Evaluate the Effect of Tiotropium Inhalation Capsules (Spiriva) on the Magnitude of Exercise, Measured Using an Accelerometer, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- A Study Based on Medical Records That Looks at the Duration of Use of Two Types of Inhalers With Different Medicines in Patients With Chronic Obstructive Pulmonary Disease (COPD)
- A Study to Evaluate Efficacy and Safety of Tiotropium in Children 6 to 11 Years Old With Moderate Asthma
- A Study Using US Medical and Pharmacy Claim Records to Compare the Resource Use, Cost, and Outcomes of People With COPD Who Take Either Tiotropium + Olodaterol or Fluticasone + Umeclidinium + Vilanterol
- A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)
- A Trial to Assess the Bioequivalence of Tiotropium Bromide Inhalation Powder in Healthy Adult Participants Under Fasting Conditions
- An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
Approved for (5)
- Asthma
- Chronic bronchitis
- Chronic obstructive pulmonary disease
- Obstructive lung disease
- Pulmonary emphysema
In development for (3)
- Cystic fibrosis Phase 2
- Neoplasm Phase 2
- Spinal cord injury Phase 2
Other linked conditions (1)
Targets (1)
- CHRM3 Muscarinic acetylcholine receptor M3 antagonist